Tacit’s programs are in preclinical development. No Tacit therapy is approved for clinical use, and safety and efficacy in humans have not been established. Development outcomes and timelines remain subject to further testing and regulatory review.
Splicing-Directed Repair™ is a trademark of Tacit Therapeutics, Inc. All other names and marks are the property of their respective owners. © 2026 Tacit Therapeutics, Inc. All rights reserved.
Privacy 